Santhera Pharmaceuticals Holding Ltd.

SANN

Equity

ISIN CH1276028821 / Valor 127602882

SIX Swiss Exchange (2024-09-17)

CHF 9.38+0.64%

Santhera Pharmaceuticals Holding Ltd.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Santhera Pharmaceuticals Holding Ltd. is a specialty pharmaceutical company based in Switzerland that focuses on the development and commercialization of innovative medicines for patients with rare diseases. The company is dedicated to addressing the unmet medical needs of individuals living with these conditions through the advancement of specialized treatments.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Santhera Pharmaceuticals Holding Ltd. reported a revenue of CHF 103.4 million for the year ended December 31, 2023. This significant revenue was primarily driven by the licensing deal with Catalyst Pharmaceuticals for AGAMREE in North America.

Net Income

For the same period, Santhera Pharmaceuticals Holding Ltd. achieved a net income of CHF 54.8 million. This positive financial outcome reflects the successful execution of strategic initiatives, including the Catalyst licensing agreement.

Cash Reserves

As of the end of 2023, Santhera Pharmaceuticals Holding Ltd. had CHF 30.4 million in cash reserves. These reserves, along with anticipated revenue from product sales, are expected to support the company's operations into 2025.

Debt Obligations

Santhera Pharmaceuticals Holding Ltd. acknowledged the need for additional funding to meet its debt obligations, including maturing convertible bonds. The company aims to achieve cash breakeven by the first half of 2026 through further market launches and strategic financial planning.

Product Launches

Santhera Pharmaceuticals Holding Ltd. successfully launched AGAMREE in Germany in January 2024, marking its first global market entry. The company plans to expand AGAMREE's availability to additional key geographies in Europe, including France, the UK, Italy, Spain, Benelux, and Switzerland.

Summarized from source with an LLMView Source

Key figures

8.31%1Y

-57.4%3Y

-92.6%5Y

Performance

60.7%1Y

74.9%3Y

71.7%5Y

Volatility